Brian F. Chapin, M.D. on the Uptake of PSMA PET in Prostate Imaging
The approval of Blue Earth Diagnostics' Posluma (flotufolastat F 18) is a significant step forward for PSMA PET imaging, but will it actually help improve patient outcomes?
This content originally appeared on our sister site, Urology Times.
Prostate cancer imaging is having its moment in the spotlight, with numerous advances in imaging agents for positron emission tomography slated to help improve diagnostics in a disease that's rife with recurrence.
The most recent news comes from Blue Earth Diagnostics, whose radioactive imaging agent Posluma (flotufolastat F 18) was recently approved in May 2023 for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
While improved imaging will certainly move the needle on diagnosis, it's yet to be seen how this will ultimately impact patient outcomes.
In an interview with our sister site, Urology Times, Brian F. Chapin, M.D., associate professor of urology at the University of Texas MD Anderson Cancer Center in Houston, spoke about the potential impact of PSMA PET and some of the challenges the clinical community is facing in the wake of these advances.
Click here for more of the latest research on prostate imaging.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
